Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

crawled date : 2022 - 02 - 15    crawled time : 00:00    save search

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
Published: 2022-02-14 (Crawled : 00:00) - biospace.com/
NMTC | $1.14 0.0% 19K twitter stocktwits trandingview |
Real Estate and Rental and Leas...
| | O: 5.74% H: 0.0% C: -7.03%

financial results one report results
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
Published: 2022-02-14 (Crawled : 00:00) - biospace.com/
MGNX | $15.62 -2.8% -2.88% 1M twitter stocktwits trandingview |
Health Technology
| | O: 0.09% H: 1.77% C: -2.99%

financial results ces conference results
Whirlpool Corporation Increases Quarterly Dividend by 25% and Share Repurchase Program Authorization by $2 Billion
Published: 2022-02-14 (Crawled : 00:00) - prnewswire.com
WHR | News A | $104.67 0.54% 0.0% 1M twitter stocktwits trandingview |
Consumer Durables
| | O: 2.52% H: 1.81% C: 1.39%
POOL | News | $361.21 -0.47% -0.47% 330K twitter stocktwits trandingview |
Distribution Services
| | O: 1.13% H: 2.41% C: 0.77%

program corporation authorization
LRES Welcomes Natalie Harrison as Director, Vendor Management
Published: 2022-02-14 (Crawled : 00:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320 twitter stocktwits trandingview |
Communications
| Email alert Add to watchlist


Walker & Dunlop Arranges $34 Million Construction Loan for Los Angeles-Area Industrial Warehouse
Published: 2022-02-14 (Crawled : 00:00) - prnewswire.com
WD 4 | $91.24 1.4% 0.0% 220K twitter stocktwits trandingview |
Finance
| | O: 2.0% H: 2.18% C: 0.79%

trial
Alkami to Announce Fourth Quarter 2021 Financial Results
Published: 2022-02-14 (Crawled : 00:00) - globenewswire.com
ALKT | News M | $23.78 -1.08% -1.09% 200K twitter stocktwits trandingview |
Information
| | O: 2.07% H: 1.45% C: 1.27%

financial results results
Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
Published: 2022-02-14 (Crawled : 00:00) - globenewswire.com
ARVN | $34.78 1.43% 1.41% 940K twitter stocktwits trandingview |
Health Technology
| | O: 1.4% H: 0.82% C: -4.78%

arv-110 protac phase 2 ongoing expansion asco phase 1
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services

NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services

INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.